From: Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer
Gene
Subset of Subjects with Pre-Treatment Tissue Biopsies (N = 47)
TP53
20 (42.6)
KRAS
12 (25.5)
KEAP1
9 (19.1)
BRAF
6 (12.8)
STK11
5 (10.6)
ERBB2
EGFR
2 (4.2)